PATENT CLAIM ANALYSIS

Application Number: 15904883
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "248000"]

Abstract:
Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR X  or CR X R Y ; if X═NR X  then n is 1 or 2 and if X═CR X R Y  then n is 1; R X  is selected from the group consisting of H, optionally substituted C 1-20  alkyl, C 5-20  aryl, C 3-20  heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R Y  is selected from H, hydroxy, amino; or R X  and R Y  may together form a spiro-C 3-7  cycloalkyl or heterocyclyl group; R C1  and R C2  are both hydrogen, or when X is CR X R Y , R C1 , R C2 , R X  and R Y , together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; andR 1  is selected from H and halo.

Claim (Index 5):
A method of treatment of cancer comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of formula (III): simultaneously or sequentially with temozolimide.

Metadata:
- Claim Count in Document: 18.0
- Percentile: 88.0
- Lexical Diversity: 2.2125
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13179353', '14483663', '11318155', '12109260', '10876080']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7400183348214184
- 35 USC 102 Novelty (BERT): 0.5336110602230106
- Combined Prediction Score: 0.7193776073615776
- Mean Citation Score: 328.860896
- Max Citation Score: 334.6997
- Similarity Product: 195.30572291143537

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test